Related Experiment Video
Updated: Jul 4, 2026

Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia
Published on: January 27, 2018
Deuruxolitinib for Alopecia Areata
Alexander Robbins1, Mariana Phillips1,2
1Virginia Tech Carilion School of Medicine, Roanoke, VA, USA.
None:
Alopecia areata (AA), an autoimmune condition characterized by non-scarring hair loss, affects 2% of the United States population. AA is a CD8 T-cell driven autoimmune disease in which the cytokines interferon-gamma and interleukin-15 play a central role in disease progression. These pathways depend on Janus kinase (JAK) signaling, making JAK inhibitors an ideal therapeutic option in treating AA. Deuruxolitinib, an oral JAK inhibitor, was approved by the US Food and Drug Administration in July 2024, for the treatment of severe AA in adults. Deuruxolitinib is the third oral JAK inhibitor approved for the treatment of severe AA, the others being baricitinib and ritlecitinib. Deuruxolitinib's mechanism of action, clinical efficacy, and safety profile in the treatment of AA are reviewed.
Related Concept Videos
Treatment Resistent Cancers
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs for Treatment of Ulcerative Colitis in IBD

